1 option
Clinical review report : indication: for the treatment of severe hypoglycemic reactions which may occur in the management of insulin treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates. Glucagon nasal powder (Baqsimi) (Eli Lilly Canada Inc) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Unconsciousness.
- Physical Description:
- 1 online resource
- Edition:
- Final (with redactions).
- Place of Publication:
- Ottawa, ON : CADTH, 2020.
- Summary:
- The objective of this review was to perform a systematic review of the beneficial and harmful effects of glucagon nasal powder (Baqsimi) for the treatment of severe hypoglycemic reactions which may occur in the management of insulin-treated patients with diabetes mellitus, when impaired consciousness precludes oral carbohydrates.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.